Microbial Biomarkers

The use of gut microbiome composition, microbial metabolites, or microbial products as diagnostic, prognostic, or monitoring tools for disease. Unlike traditional clinical biomarkers, microbial biomarkers capture the functional state of the host-microbiome ecosystem and can reflect both local (gut) and systemic disease processes.

Taxa-Based Biomarkers

Diagnostic Enrichment (Pathogen Presence)

- Fusobacterium nucleatum for colorectal cancer: Enriched in tumor tissue; detectable in stool; correlates with tumor stage, microsatellite instability, and poor prognosis. Potentially actionable (antibiotic targeting).
- porphyromonas gingivalis for atherosclerosis: Detected in atherosclerotic plaques; periodontal disease as CVD risk marker.
- Clostridioides difficile for antibiotic-associated colitis: Gold standard culture/toxin-based diagnosis.
- *Increased Clostridioides*** in ASD: Enriched in multiple cohorts; source of p-cresol and 4-EPS [zheng 2021 bacterial aromatic amino acids asd].

Diagnostic Depletion (Commensal Loss)

- faecalibacterium prausnitzii depletion for IBD: One of the most replicated microbiome findings; low F. prausnitzii predicts relapse in Crohn's disease.
- Roseburia depletion: Reduced in IBD, CVD, and T2D; reflects loss of butyrate production capacity.
- akkermansia muciniphila depletion: Low levels associated with metabolic syndrome, obesity, and response to immunotherapy.
- bifidobacterium depletion: Reduced in multiple conditions including ASD, MS, and heavy-metal-exposed populations.

Metabolite-Based Biomarkers

- tmao for CVD risk: Elevated plasma TMAO predicts major adverse cardiovascular events (MACE) including MI, stroke, and death; produced from dietary choline/carnitine by gut bacteria.
- p-Cresol sulfate for ASD: Elevated in urine and plasma of ASD children; produced from tyrosine by Clostridioides; also a uremic toxin marker in CKD [zheng 2021 bacterial aromatic amino acids asd].
- calprotectin (fecal): Neutrophil-derived protein; gold-standard non-invasive marker for intestinal inflammation in IBD.
- Indoxyl sulfate for CKD progression: Microbial indole derivative; accumulates with renal failure; cardiotoxic.
- short chain fatty acids (fecal): Reduced butyrate/propionate reflects loss of fermentative capacity; altered SCFA profiles documented in ASD, IBD, and CVD.

Metallophore-Based Biomarkers

An emerging approach that leverages microbial metal-chelating molecules as infection diagnostics [patil 2021 infection metallomics critical care]:
- Siderophores in urine: Triacetylfusarinine C (TAFC) from Aspergillus detectable within 4.5 hours of infection; more sensitive than galactomannan for invasive aspergillosis.
- Yersiniabactin: Iron- and copper-binding metallophore from uropathogenic E. coli; detectable in patient urine during UTI.
- Isotope data filtering: Mass spectrometry with metal isotope signatures can distinguish invasive infection from benign colonization -- a critical ICU distinction.

Challenges

- Individual variability: The "healthy" microbiome varies enormously between individuals, making universal thresholds difficult.
- Correlation vs. causation: Many taxa-based associations lack mechanistic validation.
- Standardization: Sample collection, DNA extraction, sequencing platform, and bioinformatics pipeline all introduce variability.
- Temporal dynamics: The microbiome fluctuates with diet, medication, and circadian rhythms.